Amador Bioscience Expands Global Drug Development Capabilities with Grand Reopening of Maryland Bioanalytical and Biomarker Laboratory
Germantown, Maryland, USA
AMADOR BIOSCIENCE Announces the Grand Opening of Its Renovated Office and Bioanalytical and Biomarker Laboratory in Germantown, Maryland, USA.Spanning over 10,000 square feet, the laboratory features functional platforms for Ligand-Binding Assay (LBA), Cell-Based Assay (CBA), Molecular Biology Assay (MBA), Flow Cytometry, LC/MS, and sample management. Equipped with state-of-the-art instrumentation, it provides bioanalysis and biomarker analysis services for various innovative therapeutic modalities in compliance with Good Laboratory Practice (GLP) and Good Clinical Practice (GCP).
From left to right: Kaia Sartori, Vice President of AMADOR Bioscience California; Rafiq Islam, Vice President of Maryland; Chief Operating Officer Chen Xiaomin; Dr. Liang Meina, Chief Technology Officer; Dr. Feng Hui, Executive Director and Chief Operating Officer of Junshi Biosciences; Dr. Zhao Xiaobin, Founder and President of Haichang Biopharma; and Dr. Wang Bing, Chairman and CEO of AMADOR Bioscience
Amador Bioscience held an internal celebration for the opening of its Phase I laboratory in Maryland on July 21 (Eastern Time). Attendees included executives from Amador US and Amador Europe, A2PG executives, and distinguished guests such as Dr. Rakesh Dixit, Former Global Vice President of Toxicology and Pathology at AstraZeneca and Scientific Advisor to Amador Bioscience; Dr. Hui Feng, Executive Director and COO of Junshi Biosciences; Dr. Patrick Liu, Founder and President of ClariGene; Dr. Xiaobin Zhao, Founder and President of Haichang Bio; Dr. Ping Cui, Senior Vice President of Coyote Pharmaceuticals; and Dr. Jiaqi Huang, Senior Vice President of CytoNiche Biotechnology.
On the same day, AMADOR BIOSCIENCE also signed an agreement for the expansion of its Maryland laboratory. Upon completion of the Phase II laboratory in the first quarter of 2023, the total area will exceed 20,000 square feet.
Signing of the Phase II Expansion Agreement for the Maryland Laboratory
Front row, from left to right: Dr. Meina Liang, CTO of AMADOR BIOSCIENCE; Andrew Davis, Representative of Sheer Partners. Back row, from left to right: Dr. Sunny Chapel, CSO of AMADOR BIOSCIENCE and CEO of A2PG Clinical Pharmacology; Dr. Nidal Huniti, President of A2PG; David Roach, CFO of AMADOR BIOSCIENCE; Kaia Sartori, Vice President of California; Xiaomin Chen, COO; Dr. Ryan Criste, Senior Director of Early Clinical Research; Rafiq Islam, Vice President of Maryland; Dr. Bing Wang, Chairman and CEO.
AMADOR BIOSCIENCE Maryland Phase II Laboratory Site
Rafiq Islam, Vice President of AMADOR Bioscience’s Maryland laboratory, and his team introduced the laboratory’s setup, management processes, and service offerings to the guests.The laboratory has introduced the latest instruments and equipment, such as the MSD S600 for high-sensitivity immunoassays, the CytoFLEX and Aurora for flow cytometry analysis, and the SCIEX Triple Quad 6500+ for precise quantitative mass spectrometry detection., he stated: “The laboratory complies with GLP/GCLP standards. Leveraging state-of-the-art facility systems and a team of experienced scientists, AMADOR BIOSCIENCE is able to provide industry-leading, high-quality bioanalysis and biomarker services, significantly enhancing its capacity to support global new drug development.”
Rafiq Islam, Vice President of AMADOR Maryland Laboratory, introduced the laboratory to the guests.
The core team of AMADOR BIOSCIENCE’s Maryland laboratory comprises scientists with many years of industry experience in bioanalysis and biomarkers. They provide professional, compliant, timely, and effective services throughout the drug development and regulatory processes across multiple therapeutic areas, covering modalities such as monoclonal antibodies, bispecific antibodies, fusion proteins, enzymes, peptides, antibody–drug conjugates (ADCs), cell and gene therapies, oligonucleotides, and vaccines.
Thomas Kees, Senior Manager of Laboratory Operations in Maryland, introduced the sample management process to the guests.
Dr. Meina Liang, CTO and President of Bioanalysis and Biomarkers at AMADOR BIOSCIENCEstated: “The establishment of the Maryland laboratory signifies that AMADOR BIOSCIENCE can provide comprehensive bioanalysis and biomarker services to regional and global clients. We will continue to emphasize compliance, robust quality, and timely delivery to help our partners achieve successful drug approvals.”
Dr. Wang Bing, Chairman and CEO of AMADOR BIOSCIENCEstated: “The upgrade of the Maryland office base and the establishment of the laboratory mark a significant milestone in enhancing AMADOR BIOSCIENCE’s global service capabilities, as well as representing a key achievement in consolidating and strengthening its leading edge in translational and early-stage clinical development.”
Amador Bioscience’s Maryland laboratory is now operational and has begun analyzing large-molecule biological samples, with its grand opening ceremony scheduled for September. The company’s laboratory in Pleasanton, located in the San Francisco Bay Area of California, is currently under intensive construction and is expected to become operational in two months. Earlier this year, Amador Bioscience completed and put into use a 70,000-square-foot laboratory in Hangzhou, China. The company is also commencing laboratory construction in Belgium, and we anticipate good news from this venture in the near future.
Amador Bioscience is a globally leading next-generation CRO specializing in translational and clinical development.
As a preferred partner for the successful development of innovative drugs, Amador Bioscience provides end-to-end services in translational science, clinical pharmacology (A2PG), regulatory submissions, and clinical development that meet international standards for new drug development in China, Europe, and the United States. These services encompass clinical development strategy and execution from preclinical stages to market launch, scientifically optimizing dose selection, target selection, and patient selection, while adhering to global quality execution standards to enhance the success rate of new drug R&D. Its client base ranges from leading startup biotechnology companies to multinational pharmaceutical enterprises. To date, the Amador team has successfully completed over 210 marketing authorization applications (NDA, BLA, MAA) in Europe and the United States for domestic and international clients.
AMADOR BIOSCIENCE has established operational facilities in multiple locations worldwide, including Pleasanton, CA; Ann Arbor, MI; Germantown, MD; and Richmond, VA in the United States; Hangzhou, Shanghai, and Beijing in China; and Limburg, Belgium in Europe.